Incretin-Based Therapies Show Real-World Efficacy Consistent with RCTs When Target Doses Attained

Despite the transformative impact of incretin-based therapies on obesity and type 2 diabetes (T2D) management, a significant gap exists between their reported efficacy in highly controlled randomized controlled trials (RCTs) and their observed effectiveness in diverse clinical populations. RCTs demonstrate substantial weight loss and glycemic improvements, yet the extent to which these translate to real-world settings, where factors like adherence, dose escalation, and patient selection vary, remains a critical question for clinicians and patients. Understanding this disparity is crucial for setting realistic expectations and optimizing treatment strategies.

This narrative review systematically compared evidence from seven 2026-published RCT meta-analyses (comprising 127 RCTs and 58,976 participants) with 26 real-world studies identified via a structured PubMed search. The comparison was descriptive, focusing on primary outcomes of body weight loss and HbA1c reduction, alongside secondary outcomes including major adverse cardiovascular events (MACE), neurological endpoints, and overall safety. The analysis specifically examined how real-world outcomes for compounds like semaglutide and tirzepatide differed from or aligned with their RCT counterparts, particularly considering dose attainment and persistence.

For patients with type 2 diabetes, real-world use of semaglutide achieved 4.7-10.5 kg weight loss over 6-12 months and 1.0-1.3 percentage-point HbA1c reductions. These figures were generally lower than meta-analytic estimates from RCTs, where tirzepatide showed a mean difference (MD) of -9.55% in weight loss versus placebo. However, in non-diabetic populations, real-world 'persister' analyses (e.g., SHAPE study) for semaglutide (-14.1% weight loss) and tirzepatide (-16.5% weight loss) closely approximated per-protocol RCT estimates (semaglutide -14.9%, tirzepatide 15 mg -20.9%). A key finding was the low rate of target dose attainment: only 13% of semaglutide users reached 2.4 mg, and 25.9% of tirzepatide users reached 15 mg. Real-world cardiovascular data demonstrated MACE reductions of 20%-46%, broadly consistent with RCT findings. High discontinuation rates (20%-50% within 1 year) and prior GLP-1 RA exposure were identified as factors contributing to the observed efficacy gap. > Real-world incretin-based therapy effectiveness is broadly consistent with RCT efficacy when dose attainment is accounted for.